ESHAP

ESHAP is an acronym for relatively intensive chemotherapy regimen that is used for salvage therapy in relapsed or refractory lymphomas and Hodgkin's lymphoma. In combination with monoclonal antibody Rituximab it is called R-ESHAP or ESHAP-R.[1]

[R]-ESHAP consists of:

  1. (R)ituximab, an anti-CD20-directed monoclonal antibody that kills both normal and malignant B-lymphocytes
  2. (E)toposide, an epipodofyllotoxin topoisomerase inhibitor
  3. (S)olu-Medrol - Methylprednisolone, which is a glucocorticoid that can lyse lymphocytes
  4. (H)igh-dose (A)ra-C - cytarabine
  5. (P)latinol - Cisplatin, a platinum-based antineoplastic agent, also an alkylating antineoplastic agent.

Dosing regimen
DrugDoseModeDays
(R)ituximab375 mg/m2IV infusionDay 0
(E)toposide40 mg/m2IV infusion over 1 hrDays 1-4
(S)olu-Medrol - Methylprednisolone500 mgIV bolus over 15 minDays 1-5
(H)igh-dose (A)ra-C — cytarabine2000 mg/m2IV infusion over 2 hrsDay 5
Platinol (cisplatin)25 mg/m2IV continuous infusion over 24 hrsDays 1-4

References
  1. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.